𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis

✍ Scribed by Amelia E. B. Moore; Glen M. Blake; Kathleen A. Taylor; Valerie A. Ruff; Asad E. Rana; Xiaohai Wan; Ignac Fogelman

Publisher
Springer
Year
2011
Tongue
English
Weight
666 KB
Volume
39
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bone material properties in actively bon
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

Changes in bone mineral density and body
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma
✍ Hang Lee; Katelyn McGovern; Joel S. Finkelstein; Matthew R. Smith πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Initial treatment with a gonadotropin‐releasing hormone (GnRH) agonist increases fat mass, decreases lean body mass, and decreases bone mineral density (BMD) in men with prostate carcinoma. To the authors' knowledge, little is known regarding either the long‐term effects